FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any …